Back to results
US 10,588,905 B2Granted
Compositions and methods for treatment of fragile X syndrome
AssigneeChildren's Hospital Medical Center
InventorsCraig Erickson, Tori Lynn Schaefer
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeChildren's Hospital Medical Center
InventorsCraig Erickson, Tori Lynn Schaefer
Estimating the term…
Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.
A composition for the treatment of one or more signs or symptoms of fragile X, comprising a therapeutically effective amount of a GABA(A) alpha 2 and/or 3, agonist or partial agonist and an agent selected from lithium, minocycline or a combination thereof,
A composition for the treatment of one or more signs or symptoms of fragile X, comprising a therapeutically effective amount of a GABA(A) alpha 2 and/or 3, agonist or partial agonist and an agent selected from atypical antipsychotics, lithium, a serotonin noradrenergic reuptake inhibitor (SNRI), non-SSRI non-SNRI serotonergic drug, a benzodiazepine, a glutamatergic drug, a GABA(B) modulator, opiate receptor modulators, endocannabinoid system modulators, a medication for the treatment of attention deficit hyperactivity disorder (ADHD), anti-epileptics, alpha 2-agonists, mGlur5 antagonists, glutamatergic agents, GABA modulators, or a combination thereof, wherein the GABA(A) alpha 2 and/or 3, agonist or partial agonist comprises
A composition for the treatment of one or more signs or symptoms of fragile X, comprising a therapeutically effective amount of
Dependencies are inferred from the claim text.